NASDAQ:ANNX Annexon Q3 2025 Earnings Results & Report $4.21 -0.02 (-0.47%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$4.26 +0.05 (+1.19%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Annexon missed analyst earnings expectations in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.37 versus the -$0.34 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call7:00 AM ET Annexon EPS ResultsActual EPS-$0.37Consensus EPS -$0.34Beat/MissMissed by -$0.03One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAnnexon Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Annexon Q3 2025 Earnings FAQ Did Annexon beat earnings estimates for Q3 2025? Annexon (NASDAQ:ANNX) reported earnings of -$0.37 per share for Q3 2025, missing the consensus estimate of -$0.34. The report was announced on Monday, November 10, 2025. Annexon Earnings HeadlinesAnnexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesNovember 9 at 8:31 PM | finance.yahoo.comAnnexon (ANNX) Projected to Announce Earnings on MondayNovember 8 at 2:26 AM | americanbankingnews.comTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.November 11 at 1:00 AM | USA Capital Gold (Ad)Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - SlideshowNovember 7, 2026 | seekingalpha.comAnnexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy TranscriptNovember 3, 2026 | seekingalpha.comAnnexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II TrialOctober 28, 2026 | marketscreener.comMSee More Annexon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email. Email Address About AnnexonAnnexon (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye. Annexon’s candidates remain in development and are not approved medicines. Founded in 2011, Annexon is headquartered in Brisbane, California. The company conducts clinical development and research to advance its antibody therapies.View Annexon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
